Literature DB >> 10830791

The role of the AT2 receptor in hypertension.

H M Siragy1.   

Abstract

The renin-angiotensin system (RAS) is integrally involved in maintaining the healthy body's hemodynamic status. It is also involved in many pathogenic situations. Angiotensin II (Ang II) is the major effector hormone of this system. Ang II subtype 1 receptor blockers (ARB), like angiotensin-converting enzyme (ACE) inhibitors, modulate the potent vasoconstricting and growth-promoting effects of Ang II. Thus, it is reasonable to assume that ACE inhibitors and ARB provide similar benefits in patients with hypertension and other diseases. There are salient differences, however, in that ARB antagonize Ang II at its AT1 receptor subtype but spare its AT2 receptor subtype, which has unique-and largely oppositional- effects on the blood vessels, kidneys, and adrenals. ACE inhibitors decrease the amount of Ang II available to its AT1 and AT2 receptors alike without totally suppressing its formation. This article reviews recent findings about the role of the AT2 receptor in both health and disease and the actions of ARB mediated by this receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830791     DOI: 10.1016/s0895-7061(00)00274-0

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  14 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7).

Authors:  Lucienne da Silva Lara; Fabíola Cavalcante; Flavia Axelband; Aloa Machado De Souza; Anibal Gil Lopes; Celso Caruso-Neves
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 3.  Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis.

Authors:  Thomas A Morinelli; Louis M Luttrell; Erik G Strungs; Michael E Ullian
Journal:  Int J Biochem Cell Biol       Date:  2016-05-07       Impact factor: 5.085

4.  The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.

Authors:  Kathryn E Husarek; Paige S Katz; Aaron J Trask; Maarten L Galantowicz; Mary J Cismowski; Pamela A Lucchesi
Journal:  Vascul Pharmacol       Date:  2015-06-30       Impact factor: 5.773

Review 5.  Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.

Authors:  Adrian J B Brady
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Interference With Endothelial PPAR (Peroxisome Proliferator-Activated Receptor)-γ Causes Accelerated Cerebral Vascular Dysfunction in Response to Endogenous Renin-Angiotensin System Activation.

Authors:  Anand R Nair; Larry N Agbor; Masashi Mukohda; Xuebo Liu; Chunyan Hu; Jing Wu; Curt D Sigmund
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 7.  The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors:  G Neil Thomas; Paul Chan; Brian Tomlinson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 8.  Inhibition of RAAS--when is it too much?

Authors:  Pablo Navarro; Robert Moskowitz; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2004-07

Review 9.  Diabetic kidney disease; review of the current knowledge.

Authors:  Heshmatollah Shahbazian; Isa Rezaii
Journal:  J Renal Inj Prev       Date:  2013-06-01

10.  AT1 and AT2 Receptor Knockout Changed Osteonectin and Bone Density in Mice in Periodontal Inflammation Experimental Model.

Authors:  Maria Laura de Souza Lima; Caroline Addison Carvalho Xavier de Medeiros; Gerlane Coelho Bernardo Guerra; Robson Santos; Michael Bader; Flavia Q Pirih; Raimundo Fernandes de Araújo Júnior; Alan B Chan; Luis J Cruz; Gerly Anne de Castro Brito; Renata Ferreira de Carvalho Leitão; Ericka Janine Dantas da Silveira; Vinicius Barreto Garcia; Agnes Andrade Martins; Aurigena Antunes de Araújo
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.